Abstract | OBJECTIVE: DATA SOURCES: An English-language literature search of PubMed and MEDLINE (Nov 2011-April 2012) was performed using the terms romidepsin, CTCL, and depsipeptide ( FK228). The National Comprehensive Cancer Network guidelines, American Society of Clinical Oncology abstracts, American Society of Hematology abstracts, clinical trial registry, and prescribing information from the manufacturer were reviewed for additional information. STUDY SELECTION AND DATA EXTRACTION: Phase 1 and 2 trials evaluating the efficacy and safety of romidepsin were reviewed with a specific focus on its use in cutaneous T-cell lymphoma. All peer-reviewed articles with clinically relevant information were evaluated for inclusion. DATA SYNTHESIS: CONCLUSIONS:
Romidepsin is an effective, durable, and well-tolerated single-agent therapy in patients with refractory CTCL and should be considered for formulary addition in this population.
|
Authors | Miryoung Kim, Lisa A Thompson, Sarah D Wenger, Cindy L O'Bryant |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 46
Issue 10
Pg. 1340-8
(Oct 2012)
ISSN: 1542-6270 [Electronic] United States |
PMID | 22968522
(Publication Type: Journal Article, Review)
|
Chemical References |
- Depsipeptides
- Histone Deacetylase Inhibitors
- romidepsin
|
Topics |
- Depsipeptides
(pharmacology, therapeutic use)
- Drug Interactions
- Histone Deacetylase Inhibitors
(pharmacology, therapeutic use)
- Humans
- Lymphoma, T-Cell, Cutaneous
(drug therapy)
- Treatment Outcome
|